Human parainfluenza viruses medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Human parainfluenza virus}} | {{Human parainfluenza virus}} | ||
==Overview== | |||
Antimicrobial therapy is indicated in infections caused by ''Parainfluenza'' virus. The drug of choice is [[Ribavirin]]. | |||
==Antimicrobial regimen== | ==Medical Therapy== | ||
===Antimicrobial regimen=== | |||
:*Parainfluenza virus<ref name="pmid23024295">{{cite journal| author=Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P| title=Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. | journal=Clin Infect Dis | year= 2013 | volume= 56 | issue= 2 | pages= 258-66 | pmid=23024295 | doi=10.1093/cid/cis844 | pmc=PMC3526251 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23024295 }} </ref> | :*Parainfluenza virus<ref name="pmid23024295">{{cite journal| author=Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P| title=Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. | journal=Clin Infect Dis | year= 2013 | volume= 56 | issue= 2 | pages= 258-66 | pmid=23024295 | doi=10.1093/cid/cis844 | pmc=PMC3526251 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23024295 }} </ref> | ||
::* 1. '''Adults''' | ::* 1. '''Adults''' | ||
| Line 14: | Line 16: | ||
:::* 1.2 '''Creatinine clearance''' | :::* 1.2 '''Creatinine clearance''' | ||
::::* 30–50 mL/min: [[Ribavirin]] PO/IV maximal 200 mg q8h | ::::* 30–50 mL/min: [[Ribavirin]] PO/IV maximal 200 mg q8h | ||
::::* 10–30 mL/ min: No recommendation can be given | ::::* 10–30 mL/min: No recommendation can be given | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Viruses]] | [[Category:Viruses]] | ||
[[Category:Infectious Disease Project]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 13:30, 20 August 2015
|
Human parainfluenza viruses Microchapters |
|
Differentiating Human parainfluenza viruses from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Human parainfluenza viruses medical therapy On the Web |
|
American Roentgen Ray Society Images of Human parainfluenza viruses medical therapy |
|
Directions to Hospitals Treating Human parainfluenza viruses |
|
Risk calculators and risk factors for Human parainfluenza viruses medical therapy |
Overview
Antimicrobial therapy is indicated in infections caused by Parainfluenza virus. The drug of choice is Ribavirin.
Medical Therapy
Antimicrobial regimen
- Parainfluenza virus[1]
- 1. Adults
- Preferred regimen: Ribavirin PO/IV 10 mg/kg q8h
- Day 1: Start with 600 mg loading dose THEN 200 mg q8h
- Day 2: 400 mg q8h
- Day 3: Increase the dose to a maximum of 10 mg/kg q8h
- 1.1 In case of adverse events
- Preferred regimen: Decrease dose or discontinue Ribavirin
- 1.2 Creatinine clearance
- 30–50 mL/min: Ribavirin PO/IV maximal 200 mg q8h
- 10–30 mL/min: No recommendation can be given
References
- ↑ Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P (2013). "Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus". Clin Infect Dis. 56 (2): 258–66. doi:10.1093/cid/cis844. PMC 3526251. PMID 23024295.